RÉSUMÉ
Nutrition is considered a key part of the management of pancreatitis in dogs and cats. While limited prospective research exists, experimental studies, retrospective studies, and anecdote allow for formulation of nutritional guidelines. Historically, fat has been considered the key nutrient of interest in pancreatitis; however, other nutrients and dietary factors, including energy density, digestibility, protein, carbohydrates, and fiber, are all of importance in these patients. Indeed protein particle size may be of greater significance than dietary fat in the management of pancreatitis in cats. Low-fat gastrointestinal diets are frequently recommended in the initial management of pancreatitis in dogs, while hydrolyzed diets are often considered first-line diets in cats with pancreatitis. The presence or absence of comorbid disease may also alter nutritional recommendations. When diseases occur concurrently, the dietary strategies for the most life-threatening illness, or the illness with the greatest impact on quality of life, is recommended to be prioritized. Many dogs and cats with pancreatitis can be transitioned back to their prediagnosis diet or another commercial maintenance diet, provided that significant comorbid disease is absent. Use of a low-fat diet in the long term may be prioritized in dogs with recurrent episodes of pancreatitis.
Sujet(s)
Maladies des chats , Maladies des chiens , Pancréatite , Animaux , Chats , Chiens , Maladies des chats/diétothérapie , Pancréatite/médecine vétérinaire , Pancréatite/diétothérapie , Maladies des chiens/diétothérapie , Phénomènes physiologiques nutritionnels chez l'animal , Aliment pour animaux/analyse , Régime alimentaire/médecine vétérinaireRÉSUMÉ
BACKGROUND: Nutritional administration in acute pancreatitis (AP) management has sparked widespread discussion, yet contradictory mortality results across meta-analyses necessitate clarification. The optimal nutritional route in AP remains uncertain. Therefore, this study aimed to compare mortality among nutritional administration routes in patients with AP using consistency model. METHODS: This study searched four major databases for relevant randomized controlled trials (RCTs). Two authors independently extracted and checked data and quality. Network meta-analysis was conducted for estimating risk ratios (RRs) with 95% confidence interval (CI) based on random-effects model. Subgroup analyses accounted for AP severity and nutrition support initiation. RESULTS: A meticulous search yielded 1185 references, with 30 records meeting inclusion criteria from 27 RCTs (n = 1594). Pooled analyses showed the mortality risk reduction associated with nasogastric (NG) (RR = 0.34; 95%CI: 0.16-0.73) and nasojejunal (NJ) feeding (RR = 0.46; 95%CI: 0.25-0.84) in comparison to nil per os. Similarly, NG (RR = 0.45; 95%CI: 0.24-0.83) and NJ (RR = 0.60; 95%CI: 0.40-0.90) feeding also showed lower mortality risk than total parenteral nutrition. Subgroup analyses, stratified by severity, supported these findings. Notably, the timing of nutritional support initiation emerged as a significant factor, with NJ feeding demonstrating notable mortality reduction within 24 and 48 h, particularly in severe cases. CONCLUSION: For severe AP, both NG and NJ feeding appear optimal, with variations in initiation timings. NG feeding does not appear to merit recommendation within the initial 24 h, whereas NJ feeding is advisable within the corresponding timeframe following admission. These findings offer valuable insights for optimizing nutritional interventions in AP.
Sujet(s)
Nutrition entérale , Méta-analyse en réseau , Soutien nutritionnel , Pancréatite , Essais contrôlés randomisés comme sujet , Humains , Pancréatite/mortalité , Pancréatite/diétothérapie , Nutrition entérale/méthodes , Soutien nutritionnel/méthodes , Intubation gastro-intestinale , Maladie aigüeRÉSUMÉ
Severe acute pancreatitis (SAP) leads to numerous inflammatory and nutritional disturbances. All SAP patients are at a high nutritional risk. It has been proven that proper nutrition significantly reduces mortality rate and the incidence of the infectious complications in SAP patients. According to the literature, early (started within 24-48 h) enteral nutrition (EN) is optimal in most patients. EN protects gut barrier function because it decreases gastrointestinal dysmotility secondary to pancreatic inflammation. Currently, the role of parenteral nutrition (PN) in SAP patients is limited to patients in whom EN is not possible or contraindicated. Early versus delayed EN, nasogastric versus nasojejunal tube for EN, EN versus PN in SAP patients and the role of immunonutrition (IN) in SAP patients are discussed in this review.
Sujet(s)
Soutien nutritionnel/méthodes , Pancréatite/diétothérapie , Guides de bonnes pratiques cliniques comme sujet , HumainsRÉSUMÉ
BACKGROUND: the incidence of childhood acute pancreatitis has been increasing in the last two decades. The number of studies on the effects of diet on the pathogenesis of pancreatitis is very small. The aim of this study was to evaluate adherence to the Mediterranean diet among children with acute pancreatitis. MATERIAL AND METHOD: this study was conducted by administering the Mediterranean Diet Quality Index (KIDMED) to 100 children -children diagnosed with acute pancreatitis (n = 50) and a control group (n = 50). RESULTS: there was a statistically significant difference between groups in terms of body mass index Z-score (p = 0.017). When the KIDMED scores of the children diagnosed with pancreatitis (4.48 ± 2.45) and the control group (6.62 ± 2.18) were compared, the KIDMED scores of the children diagnosed with pancreatitis group were significantly lower (u = 638.5; p < 0.001). Those with a moderate KIDMED index (score: 4-7) (OR: 3.734, 95 % CI, 1.068-13.058, p = 0.039) and those with a poor KIDMED index (score ≤ 3) (OR: 6.444, 95 % CI, 1.595 -26.075, p = 0.009) were found to have an increased risk of developing pancreatitis. It was found that the risk of pancreatitis increased with age (OR: 1.136, 95 % CI, 1.020-1.266, p = 0.021). CONCLUSION: according to the data obtained from our study, it was found that the pancreatitis group had poorer dietary habits than the control group. Larger and multicenter studies are needed to evaluate the role of diet in pancreatitis development
INTRODUCCIÓN: la incidencia de la pancreatitis aguda infantil ha aumentado en las últimas dos décadas. La pancreatitis aguda es una inflamación reversible del páncreas que comienza con una lesión de las células acinares. El diagnostico de pancreatitis aguda se realiza según los criterios INSPPIRE. El número de estudios sobre los efectos de la dieta en la patogenia de la pancreatitis es muy pequeño. El objetivo de este estudio fue evaluar la adherencia a la dieta mediterránea de los niños con pancreatitis aguda. MATERIAL Y MÉTODOS: este estudio se realizó administrando el Índice de Calidad de la Dieta Mediterránea (KIDMED) a 100 niños: niños diagnosticados de pancreatitis aguda (n = 50) y un grupo de control (n = 50). RESULTADOS: hubo una diferencia estadísticamente significativa entre los grupos en términos del puntaje Z del índice de masa corporal (p = 0,017). Cuando se compararon las puntuaciones KIDMED de los niños diagnosticados de pancreatitis (4,48 ± 2,45) y del grupo de control (6,62 ± 2,18), las puntuaciones KIDMED del grupo diagnosticado de pancreatitis fueron significativamente más bajas (u = 638,5; p < 0,001). Aquellos con un índice KIDMED moderado (puntaje: 4-7) (OR: 3,734; IC 95 %: 1,068-13,058, p = 0,039) y aquellos con un índice KIDMED pobre (puntaje ≤ 3) (OR: 6,444; IC 95%: 1,595-26,075, p = 0,009) presentaban mayor riesgo de desarrollar pancreatitis. Se encontró que el riesgo de pancreatitis aumentaba a medida que aumentaba la edad (OR: 1,136; IC 95%: 1,020-1,266, p = 0,021). CONCLUSIÓN: según los datos obtenidos de nuestro estudio, se encontró que el grupo con pancreatitis presentaba peores hábitos alimentarios que el grupo de control. Se necesitan estudios más grandes y multicéntricos para evaluar el papel de la dieta en el desarrollo de la pancreatitis
Sujet(s)
Humains , Mâle , Femelle , Enfant d'âge préscolaire , Enfant , Adolescent , Régime méditerranéen , Pancréatite/diétothérapie , Pancréatite/diagnostic , Études cas-témoins , Adhésion aux directives/statistiques et données numériques , Pancréatite/épidémiologie , Indice de masse corporelle , Anthropométrie , Enquêtes et questionnaires , Comportement alimentaireRÉSUMÉ
OBJECTIVE: To establish the optimal time to start oral refeeding in mild and moderate acute pancreatitis (AP) to reduce hospital length-of-stay (LOS) and complications. SUMMARY BACKGROUND DATA: Oral diet is essential in mild and moderate AP. The greatest benefits are obtained if refeeding starts early; however, the definition of "early" remains controversial. METHODS: This multicenter, randomized, controlled trial (NCT03829085) included patients with a diagnosis of mild or moderate AP admitted consecutively to 4 hospitals from 2017 to 2019. Patients were randomized into 2 treatment groups: immediate oral refeeding (IORF) and conventional oral refeeding (CORF). The IORF group (low-fat-solid diet initiated immediately after hospital admission) was compared to CORF group (progressive oral diet was restarted when clinical and laboratory parameters had improved) in terms of LOS (primary endpoint), pain relapse, diet intolerance, complications, and, hospital costs. RESULTS: One hundred and thirty one patients were included for randomization. The mean LOS for the IORF and CORF groups was 3.4 (SD ± 1.7) and 8.8 (SD ± 7.9) days, respectively (P < 0.001). In the CORF group alone, pain relapse rate was 16%. There were fewer complications (8% vs 26%) and health costs were twice as low, with a savings of 1325.7/patient in the IORF than CORF group. CONCLUSIONS: IORF is safe and feasible in mild and moderate AP, resulting in significantly shorter LOS and cost savings, without causing adverse effects or complications.
Sujet(s)
Nutrition entérale/méthodes , Pancréatite/diétothérapie , Sujet âgé , Économies , Femelle , Humains , Durée du séjour/statistiques et données numériques , Mâle , Adulte d'âge moyen , Complications postopératoires/prévention et contrôle , EspagneRÉSUMÉ
BACKGROUND: This study aims to assess the effect of early enteral nutrition support (EENS) for the management of acute severe pancreatitis (ASP). METHODS: This study will search Cochrane Library, PUBMED, EMBASE, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, CNKI, and WANGFANG from their inception to the present without language limitations. In addition, this study will also search clinical trial registry and reference lists of included trials. Eligible comparators will be standard care, medications, and any other interventions. Two authors will independently scan all citations, titles/abstracts, and full-text studies. The study methodological quality will be appraised using Cochrane risk of bias tool. If it is possible, we will pool out data and perform meta-analysis. Strength of evidence for each main outcome will be evaluated using the Grading of Recommendations Assessment, Development, and Evaluation. RESULTS: This study will summarize the most recent evidence to assess the effect of EENS for the management of ASP. CONCLUSION: The findings of this study will help to determine whether EENS is effective for patients with ASP. STUDY REGISTRATION: INPLASY202070009.
Sujet(s)
Protocoles cliniques , Nutrition entérale/normes , Soutien nutritionnel/normes , Pancréatite/diétothérapie , Prise en charge de la maladie , Nutrition entérale/méthodes , Humains , Soutien nutritionnel/méthodes , Pancréatite/physiopathologie , Revues systématiques comme sujetRÉSUMÉ
BACKGROUND: Omega-3 fatty acids (OM3-FAs) are recommended with a low-fat diet for severe hypertriglyceridemia (SHTG), to reduce triglycerides and acute pancreatitis (AP) risk. A low-fat diet may reduce pancreatic lipase secretion, which is required to absorb OM3-ethyl esters (OM3-EEs), but not OM3-carboxylic acids (OM3-CAs). METHODS: In this exploratory, randomized, open-label, crossover study, 15 patients with SHTG and previous AP were instructed to take OM3-CA (2 g or 4 g) and OM3-EE 4 g once daily for 4 weeks, while adhering to a low-fat diet. On day 28 of each treatment phase, a single dose was administered in the clinic with a liquid low-fat meal, to assess 24-h plasma exposure. Geometric least-squares mean ratios were used for between-treatment comparisons of baseline (day 0)-adjusted area under the plasma concentration versus time curves (AUC0-24) and maximum plasma concentrations (Cmax) for eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). RESULTS: Before initiating OM3-FA treatment, mean baseline fasting plasma EPA + DHA concentrations (nmol/mL) were 723 for OM3-CA 2 g, 465 for OM3-CA 4 g and 522 for OM3-EE 4 g. At week 4, mean pre-dose fasting plasma EPA + DHA concentrations increased by similar amounts (+ 735 - + 768 nmol/mL) for each treatment. During the 24-h exposure assessment (day 28), mean plasma EPA + DHA increased from pre-dose to the maximum achieved concentration by + 32.7%, + 45.8% and + 3.1% with single doses of OM3-CA 2 g, OM3-CA 4 g and OM3-EE 4 g, respectively. Baseline-adjusted AUC0-24 was 60% higher for OM3-CA 4 g than for OM3-EE 4 g and baseline-adjusted Cmax was 94% higher (both non-significant). CONCLUSIONS: Greater 24-h exposure of OM3-CA versus OM3-EE was observed for some parameters when administered with a low-fat meal at the clinic on day 28. However, increases in pre-dose fasting plasma EPA + DHA over the preceding 4-week dosing period were similar between treatments, leading overall to non-significant differences in baseline (day 0)-adjusted AUC0-24 and Cmax EPA + DHA values. It is not clear why the greater 24-h exposure of OM3-CA versus OM3-EE observed with a low-fat meal did not translate into significantly higher pre-dose fasting levels of DHA + EPA with longer-term use. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02189252, Registered 23 June 2014.
Sujet(s)
Régime pauvre en graisses , Acides gras omega-3/administration et posologie , Hypertriglycéridémie/diétothérapie , Pancréatite/diétothérapie , Sujet âgé , Aire sous la courbe , Études croisées , Compléments alimentaires , Acide docosahexaénoïque/administration et posologie , Acide docosahexaénoïque/sang , Acide eicosapentanoïque/administration et posologie , Acide eicosapentanoïque/sang , Jeûne/sang , Acides gras omega-3/sang , Femelle , Humains , Hypertriglycéridémie/complications , Hypertriglycéridémie/anatomopathologie , Mâle , Adulte d'âge moyen , Pancréatite/étiologie , Pancréatite/anatomopathologie , Triglycéride/sangRÉSUMÉ
SCOPE: Short-peptide-based enteral nutrition (SPEN) is absorbed more efficiently in patients with severe acute pancreatitis (SAP). More importantly, SPEN decreases SAP-induced enterogenous infection risk. This study aims to investigate whether SPEN alleviates intestinal bacterial translocation in mice with SAP, and the underlying mechanisms. METHODS AND RESULTS: The SAP model is established after pre-treatment with SPEN or intact-protein-based enteral nutrition. Although there is no improvement in pancreas injury, as evaluated through Hematoxylin-Eosin staining or serum amylase, SPEN obviously attenuates intestinal bacterial translocation after SAP. To unveil the mechanisms, it is found that the intestinal mechanical barrier destroyed by SAP is significantly relieved by SPEN, which presents with recovered ZO-1 expression, mucus layer, and goblet cell function. Additionally, SPEN alleviates local CCR6/CCL20 induced CD11c+ dendritic cell infiltration, systemic immunosuppression, and inhibits the secretion of luminal secretory immunoglobulin A. Possibly responsible for SAP-induced mucosal dysfunctions, destroyed intestinal mucosal microcirculation and local hypoxia are largely improved in SAP+SPEN group. CONCLUSION: SPEN can improve downregulated intestinal mucosal microcirculation secondary to SAP, which may be responsible for mucosal inflammation relief, maintenance of the mechanical barrier and mucosal immunity, the correction of systemic immunosuppression, and play a protective role in defending commensal bacterial translocation after SAP.
Sujet(s)
Nutrition entérale/méthodes , Pancréatite/diétothérapie , Pancréatite/microbiologie , Animaux , Chimiokine CCL20/métabolisme , Cellules dendritiques/anatomopathologie , Tolérance immunitaire/effets des médicaments et des substances chimiques , Muqueuse intestinale/vascularisation , Muqueuse intestinale/effets des médicaments et des substances chimiques , Mâle , Souris de lignée C57BL , Microcirculation/effets des médicaments et des substances chimiques , Peptides/composition chimique , Peptides/pharmacocinétique , Récepteurs CCR6/métabolismeRÉSUMÉ
Nutritional support is a crucial issue in Acute Pancreatitis (AP) management. Recommendations on nutrition in AP are still not completely translated in the clinical practice. We aimed to compare and evaluate the effects of parenteral nutrition (PN) vs oral/enteral nutrition (EN) on several clinical and economic outcomes in AP. This is a retrospective monocentric study conducted in a tertiary care center for pancreatic diseases. The primary outcomes were length of hospital stay (LOS) and associated costs. The secondary outcomes were the use and cost of antibiotics and fluid therapy, and the complication's rates. One hundred seventy-one patients were included from January 2015 to January 2018. Patients were 69 (40.4%) in PN group and 102 (59.6%) in EN group. There was a significant reduction in LOS in EN vs PN group in both mild AP (p < 0.0001), and moderate-severe AP (p < 0.005). There was a significant reduction in the total hospitalization costs in EN group vs PN group in both mild AP (p < 0.0001), and moderate-severe AP (p < 0.005). There was a significant reduction in the total costs of antibiotics and pain therapy in EN vs PN group (p < 0.0001 and p = 0.05, respectively). Finally, a significant reduction in the infected peri-pancreatic fluid collections rate (p = 0.04) was observed in EN vs PN group. The use of EN in AP is associated with substantial clinical and economic benefits. Thus, the application of the standard of care in nutrition and following AP guidelines is the best way to cure patients and improve healthcare system costs.
Sujet(s)
Nutrition entérale/économie , Coûts hospitaliers/statistiques et données numériques , Pancréatite/diétothérapie , Nutrition parentérale/économie , Antibactériens/économie , Femelle , Traitement par apport liquidien/économie , Humains , Italie , Durée du séjour/économie , Mâle , Adulte d'âge moyen , Études rétrospectives , Centres de soins tertiairesRÉSUMÉ
OBJECTIVE: Despite the fact that pediatric pancreatitis is an uncommon disease, its prevalence has increased in recent years. Nevertheless, until 4 years ago, the lack of nutritional guidelines for pediatric pancreatitis was evident, with all recommendations being based on clinical practice guidelines (CPGs) for adults. The aim of the present study was to review and critically appraise guidelines for the medical nutrition therapy (MNT) of pediatric pancreatitis. METHODS: A comprehensive search was performed in electronic databases (PubMed, Scopus, National Institute for Health and Care Excellence), the International Guidelines Network, BMJ best practice, and the Scottish Intercollegiate Guidelines Network to identify CPGs on the MNT of pediatric pancreatitis. The validated AGREE II tool was used for guidelines appraisal by a team of 3 independent multidisciplinary reviewers. RESULTS: A total of 4 CPGs were retrieved with pediatric pancreatitis MNT information. Out of the 4 advising bodies in total, the joint society paper published by the ESPGHAN/NASPGHAN received the highest score in almost all domains, whereas the Belgian consensus obtained the lowest score in all domains but stakeholder involvement, and was not recommended by 2 out of 3 reviewers. CONCLUSIONS: Pediatric pancreatitis guidelines appear heterogenous in quality, rigour, and transparency. Our study points out existing gaps and biases in the CPGs, and delineates the need for improving the domains identified as being of low-quality.
Sujet(s)
Pancréatite/diétothérapie , Guides de bonnes pratiques cliniques comme sujet/normes , Enfant , Humains , Thérapie nutritionnelle/méthodesRÉSUMÉ
Dietary supplementation of polyphenol-rich pomegranate extract (POMx) has been shown to have anti-oxidant and anti-inflammatory activities. Here, we evaluate the efficacy of POMx in mitigating pancreatitis in mice and provide a mechanistic outline of the process. Age-matched male Swiss albino mice were injected with Lipopolysaccharide (LPS) and given POMx supplement alone or in combination with LPS. After 4 weeks of treatment histological scoring for pancreatic edema and vacuolization was performed. Serum insulin levels were estimated and the glucose tolerance test (IPGTT) data revealed that POMx reduced inflammation induced hyperglycemia in mice. Analysis of TLR4, IκB expression, and NF-κB nuclear translocation, and concentrations of IL-6 and TNFα showed that POMx is able to modulate the molecular instigators of inflammatory responses. Annexin V assay indicated that POMx protects against inflammation-mediated apoptosis in the pancreas. Expression profile of SAPK/JNK pathway, p53, Bax, Bcl-2 and Caspase-3 validate an apoptotic to survival shift in POMx treatment group. Co-immunoprecipitation studies show that POMx stabilizes p21 and Nrf2 interaction and increases its nuclear translocation. The study also proves that the nuclear fraction of Nrf2 is able to bind to the Bcl-2 promoter and activate an anti-apoptotic program. The findings of our study underline an anti-inflammatory, anti-oxidative and anti-apoptotic role of POMx and provide a mechanistic idea of how POMx confers protection during pancreatitis.
Sujet(s)
Inhibiteur p21 de kinase cycline-dépendante/métabolisme , Facteur-2 apparenté à NF-E2/métabolisme , Pancréatite/diétothérapie , Extraits de plantes/pharmacologie , Grenadier commun/composition chimique , Animaux , Apoptose/effets des médicaments et des substances chimiques , Apoptose/physiologie , Caspase-3/génétique , Caspase-3/métabolisme , Survie cellulaire/effets des médicaments et des substances chimiques , Cytokines/sang , Compléments alimentaires , Lipopolysaccharides/toxicité , Mâle , Souris , Facteur-2 apparenté à NF-E2/génétique , Stress oxydatif/effets des médicaments et des substances chimiques , Pancréas/anatomopathologie , Pancréatite/induit chimiquement , Pancréatite/métabolisme , Pancréatite/anatomopathologie , Protéines proto-oncogènes c-bcl-2/génétiqueRÉSUMÉ
We conducted a comprehensive analysis to evaluate the treatment efficacy and safety of enteral nutrition (EN) and parenteral nutrition (PN) in severe acute pancreatitis (SAP) patients, and to provide a basis for their evidence based application in a clinical setting. We conducted a systematic online search of the PubMed, Web of Science, Wanfang, and China National Knowledge Infrastructure databases, from their inception to November 2017. Studies were subjected to further screening if they met the inclusion/exclusion criteria. Eleven studies were subjected to qualitative and quantitative synthesis; these included a total of 562 patients (281 for EN and 281 for PN). No significant heterogeneity across studies was found. The results indicated that EN can significantly decrease the mortality rate (relative risk [RR] = 0.43, 95% confidence interval [CI]: 0.23-0.78, P=0.006), and lowers the risk of infection and complications (RR = 0.53, 95% CI: 0.39-0.71, P=0.000) more so than does PN. The EN group had a similar risk of multiple organ failure (MOF) compared with the PN group (RR = 0.63, 95% CI: 0.39-1.02, P=0.059). The use of EN was also found to significantly reduce mean hospitalization time (mean difference = -2.93, 95% CI: -4.52-1.34, P=0.000). No publication bias was found. Our meta-analysis suggested that EN, but not PN, significantly reduced the risk of mortality, infection, and complications for patients with SAP. EN support also decreased the rate of MOF and surgical intervention. EN is recommended as an initial treatment option for patients with SAP.
Sujet(s)
Nutrition entérale , Pancréatite/diétothérapie , Nutrition parentérale , Maladie aigüe/épidémiologie , Adulte , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Évaluation de l'état nutritionnel , Pancréatite/physiopathologie , Essais contrôlés randomisés comme sujet , Risque , Résultat thérapeutiqueRÉSUMÉ
Objective This study was performed to systematically compare the safety and efficacy of total enteral nutrition (TEN) and total parenteral nutrition (TPN) for patients with severe acute pancreatitis (SAP). Methods The PubMed database was searched up to January 2017, and nine studies were retrieved. These studies were selected according to specific eligibility criteria. The methodological quality of each trial was assessed, and the study design, interventions, participant characteristics, and final results were then analyzed by Review Manager 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Results Nine relevant randomized controlled trials involving 500 patients (244 patients in the TEN group and 256 patients in the TPN group) were included in the meta-analysis. Pooled analysis showed a significantly lower mortality rate in the TEN than TPN group [odds ratio (OR), 0.31; 95% confidence interval (CI), 0.18-0.54]. The duration of hospitalization was significantly shorter in the TEN than TPN group (mean difference, -0.59; 95% CI, -2.56-1.38). Compared with TPN, TEN had a lower risk of pancreatic infection and related complications (OR, 0.41; 95% CI, 0.22-0.77), organ failure (OR, 0.17; 95% CI, 0.06-0.52), and surgical intervention (OR, 0.17; 95% CI, 0.05-0.62). Conclusions This meta-analysis indicates that TEN is safer and more effective than TPN for patients with SAP. When both TEN and TPN have a role in the management of SAP, TEN is the preferred option.
Sujet(s)
Nutrition entérale , Pancréatite/diétothérapie , Nutrition parentérale totale , Maladie aigüe , Humains , Essais contrôlés randomisés comme sujet , Résultat thérapeutiqueRÉSUMÉ
Enteral nutrition is preferred over parenteral nutrition as a result of the greater safety of enteral nutrition therapy and comparative convenience. A wide variety of enteral nutrition products have been developed, including disease-specific products to help manage the nutritional needs of patients with kidney failure, liver failure, lung disease, diabetes, and other conditions. An assessment of each patient's nutritional needs and digestive function should be conducted prior to initiation of enteral nutrition therapy. Other considerations in determining the appropriate route and method of enteral nutrition administration include the time and nursing involvement required for administration, potential complications of medication administration, and concerns related to pancreatic dysfunction in certain groups. Tailored guidelines and treatment considerations are reviewed in this manuscript the application of enteral nutrition in various patient populations.
Sujet(s)
Nutrition entérale/méthodes , Facteurs âges , Acides aminés/administration et posologie , Mucoviscidose/diétothérapie , Hydrates de carbone alimentaires/administration et posologie , Matières grasses alimentaires/administration et posologie , Protéines alimentaires/administration et posologie , Voies d'administration de substances chimiques et des médicaments , Calendrier d'administration des médicaments , Interactions médicamenteuses , Nutrition entérale/effets indésirables , Humains , Maladies inflammatoires intestinales/diétothérapie , Maladies métaboliques/diétothérapie , Évaluation de l'état nutritionnel , Obésité/diétothérapie , Maladies du pancréas/complications , Pancréatite/diétothérapie , Guides de bonnes pratiques cliniques comme sujet , Facteurs tempsRÉSUMÉ
The recently published guidelines for acute pancreatitis (AP) suggest that enteral nutrition (EN) should be the primary therapy in patients suffering from severe acute pancreatitis (SAP); however, none of the guidelines have recommendations on mild and moderate AP (MAP). A meta-analysis was performed using the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P). The following PICO (problem, intervention, comparison, outcome) was applied: P: nutrition in AP; I: enteral nutrition (EN); C: nil per os diet (NPO); and O: outcome. There were 717 articles found in Embase, 831 in PubMed, and 10 in the Cochrane database. Altogether, seven SAP and six MAP articles were suitable for analyses. In SAP, forest plots were used to illustrate three primary endpoints (mortality, multiorgan failure, and intervention). In MAP, 14 additional secondary endpoints were analyzed (such as CRP (C-reactive protein), WCC (white cell count), complications, etc.). After pooling the data, the Mann-Whitney U test was used to detect significant differences. Funnel plots were created for testing heterogeneity. All of the primary endpoints investigated showed that EN is beneficial vs. NPO in SAP. In MAP, all of the six articles found merit in EN. Analyses of the primary endpoints did not show significant differences between the groups; however, analyzing the 17 endpoints together showed a significant difference in favor of EN vs. NPO. EN is beneficial compared to a nil per os diet not only in severe, but also in mild and moderate AP.
Sujet(s)
Diétothérapie/méthodes , Nutrition entérale/méthodes , État nutritionnel/physiologie , Pancréatite/diétothérapie , Nutrition parentérale/méthodes , Régime alimentaire/méthodes , HumainsSujet(s)
Nutrition entérale , Intubation gastro-intestinale , Pancréatite/diétothérapie , Femelle , Humains , MâleRÉSUMÉ
Presentamos un caso de pancreatitis aguda severa inducida por hipertrigliceridemia secundaria a déficit de lipoproteín lipasa (LPL) en una paciente gestante con diabetes gestacional, manejada inicialmente con dieta, siendo necesario posteriormente llevar a cabo medidas de soporte nutricional artificial: nutrición parenteral total. El déficit de LPL causa hipertrigliceridemia severa y, frecuentemente, pancreatitis aguda de repetición, situación de difícil manejo y de importante gravedad durante la gestación. La pancreatitis aguda por hipertrigliceridemia familiar supone el 5% de los casos, incluyéndose el déficit de LPL. El objetivo del tratamiento será alcanzar niveles de triglicéridos inferiores a 500 mg/dl, siendo la dieta muy baja en grasa el tratamiento de elección, pudiéndose asociar también fármacos o técnicas de plasmaféresis. La nutrición parenteral total enriquecida en ácidos grasos w3 y glutamina resultó segura y eficaz en la paciente, con un descenso importante de los niveles de triglicéridos (AU)
We present a case of severe acute pancreatitis induced by hypertriglyceridemia secondary to lipoprotein lipase (LPL) deficiency in a pregnant patient with gestational diabetes, initially maneged with diet but it was later necessary to carry out artificial nutricional support measures: total parenteral nutrition. LPL deficiency might cause severe hypertriglyceridemia, repetition acute pancreatitis which is an unwieldy and severe situation during pregnancy. Acute familial hypertriglyceridemia pancreatitis accounts for 5% of cases, including LPL deficiency. The goal of treatment is to reach triglycerides levels below 500 mg/dl, being very low fat diet the treatment of choice, drugs or plasmapheresis techniques can also be associated. TPN enriched in w3 fatty acids and glutamine was safe and effective in our patient with significant decrease in triglyceride levels (AU)
Sujet(s)
Humains , Nutrition parentérale totale/méthodes , Pancréatite/diétothérapie , Solutions d'alimentation parentérale/usage thérapeutique , Lipoprotein lipase/analyse , Hypertriglycéridémie/épidémiologie , PlasmaphérèseRÉSUMÉ
The content and fatty acid composition of phospholipids and esterified cholesterol were studied in the blood plasma of rabbits under acute arginine pancreatitis and its correction using linseed oil. It is established that the transport and anti-inflammatory functions of blood plasma deteriorates under acute arginine pancreatitis due to a decrease of the content of polyunsaturated fatty acids in phospholipids. The amount of cholesterol esterified with saturated and monounsaturated fatty acids increases in the blood plasma of rabbits. The concentration of phospholipids and esterified cholesterol is normalized and their fatty acid composition is improved in the lipid composition of the blood plasma of rabbits with acute arginine pancreatitis fed with linseed oil.